Abstract
The wild-type protein product of the p53 tumor suppressor gene can activate transcription of genes which are involved in mediating either growth arrest, e.g. WAF1 or apoptotis, e.g. BAX and PIG3. Additionally, p53 can repress a variety of promoters, which, in turn, may be responsible for the functional activities exhibited by p53. This study shows that the Q22, S23 double mutation, which is known to inactivate a p53 trans-activation subdomain located within the initial 40 residues of the protein, while abrogating transactivation from the WAF1 promoter, only attenuates apoptosis triggering, transactivation from other p53-responsive promoters and repression of promoters by p53. The Q53, S54 double mutation, which inactivates another p53 transactivation subdomain situated between amino acids 43 and 73 results in attenuation of all of the afore-mentioned p53 activities. In contrast to the Q22, S23 double mutation, this latter mutation set does not alter mdm-2-mediated inhibition and degradation of p53. Finally, mutation of all four residues results in complete abrogation of every p53 activity mentioned above.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bargonetti J, Manfredi J, Chen X, Marshak D and Prives C. . 1993 Genes Dev. 7: 2565–2574.
Bates S and Vousden K. . 1996 Curr. Opin. Genet. Dev. 6: 12–18.
Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger B and Kley N. . 1995 Nature 377: 646–649.
Caelles C, Helmberg A and Karin M. . 1994 Nature 370: 220–223.
Candau R, Scolnick D, Darpino P, Ying C, Halazonetis T and Berger S. . 1997 Oncogene 15: 807–816.
Chang J, Kim D, Lee S, Choi K and Sung Y. . 1995 J. Biol. Chem. 270: 25014–25019.
Chen X, Ko L and Prives C. . 1996 Genes Dev. 10: 2438–2451.
Cho Y, Gorina S, Jeffrey P and Pavletich N. . 1994 Science 265: 346–355.
Clore G, Omichinski J, Sakaguchi K, Zambrano N, Sakamoto H, Appella E and Gronenborn A. . 1994 Science 265: 386–391.
Conseiller E, Debussche L, Landais D, Venot C, Maratrat M, Sierra V, Tocqué B and Bracco L. . 1998 J. Clin. Invest. 101: 123–127.
Cress WD and Triezenberg SJ. . 1991 Science 251: 87–90.
Dubs-Poterszman M, Tocqué B and Wasylyk B. . 1995 Oncogene 11: 2445–2449.
El-Deiry W, Kern S, Pietenpol J, Kinzler K and Vogelstein B. . 1992 Nat. Genet. 1: 45–49.
Friedlander P, Haupt Y, Prives C and Oren M. . 1996 Mol. Cell. Biol. 16: 4961–4971.
Funk W, Pak D, Karas R, Wright W and Shay J. . 1992 Mol. Cell. Biol. 12: 2866–2871.
Gottlieb T and Oren M. . 1996 Biochim. Biophys. Acta. 1287: 77–102.
Hansen R and Oren M. . 1997 Curr. Opin. Genet. Dev. 7: 46–51.
Haupt Y, Rowan S, Shaulian E, Vousden K and Oren M. . 1995 Genes Dev. 9: 2170–2183.
Haupt Y, Barak Y and Oren M. . 1996 EMBO J. 15: 1596–1606.
Haupt Y, Maya R, Kazaz A and Oren M. . 1997 Nature 387: 296–299.
Hollstein M, Sidransky D, Vogelstein B and Harris C. . 1991 Science 253: 49–53.
Israeli D, Tessler E, Haupt Y, Elkeles A, Wilder S, Amson R, Telerman A and Oren M. . 1997 EMBO J. 16: 4384–4392.
Jeffrey P, Gorina S and Pavletich N. . 1995 Science 267: 1498–1502.
Ko L and Prives C. . 1996 Genes Dev. 10: 1054–1072.
Kubbutat M, Jones S and Vousden K. . 1997 Nature 387: 299–303.
Levine A. . 1997 Cell 88: 323–331.
Lin J, Chen J, Elenbaas B and Levine A. . 1994 Genes Dev. 8: 1235–1246.
Lu H and Levine A. . 1995 Proc. Natl. Acad. Sci. USA 92: 5154–5158.
Ludwig R, Bates S and Vousden K. . 1996 Mol. Cell. Biol. 16: 4952–4960.
Miyashita T and Reed J. . 1995 Cell 80: 293–299.
Murphy M, Hinman A and Levine A. . 1996 Genes Dev. 10: 2971–2980.
Roemer K and Mueller-Lantzsch N. . 1996 Oncogene 12: 2069–2079.
Owen-Schaub L, Zhang W, Cusack J, Angelo L, Santee S, Fujiwara T, Roth J, Deisseroth A, Zhang W and Kruzel E et al. 1996 Mol. Cell. Biol. 15: 3032–3040.
Pavletich N, Chambers K and Pabo C. . 1993 Genes Dev. 7: 2556–2564.
Polyak K, Xia Y, Zweier J, Kinzler K and Vogelstein B. . 1997 Nature 389: 300–305.
Regier JL, Shen F and Triezenberg SJ. . 1993 Proc. Natl. Acad. Sci. USA 88: 7605–7609.
Rowan S, Ludwig R, Haupt Y, Bates S, Lu X, Oren M and Vousden K. . 1996 EMBO J. 15: 827–838.
Sturzbecher H, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E and Jenkins J. . 1992 Oncogene 7: 1513–1523.
Thut C, Chen J, Klemm R and Tjian R. . 1995 Science 267: 100–104.
Unger T, Nau M, Segal S and Minna J. . 1992 EMBO J. 11: 1383–1390.
Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L and Debussche L. . 1998 EMBO J. 17: 4668–4679.
Wagner A, Kokontis J and Hay N. . 1994 Genes Dev. 8: 2817–2830.
Walker K and Levine A. . 1996 Proc. Natl. Acad. Sci. USA 93: 15335–15340.
Wu G, Burns T, McDonald III E, Jiang W, Meng R, Krantz I, Kao G, Gan D, Zhou J, Muschel R, Hamilton S, Spinner N, Markowitz S, Wu G and El-Deiry W. . 1997 Nature Genetics 17: 141–143.
Wu G, Saftig P, Peters C and El-Deiry W. . 1998 Oncogene 16: 2177–2185.
Yonish-Rouach E, Borde J, Gotteland M, Mishal Z, Viron A and May E. . 1994 Cell Death and Differ. 1: 39–47.
Zhu J, Zhou W, Jiang J and Chen X. . 1998 J. Biol. Chem. 21: 13030–13036.
Acknowledgements
We gratefully acknowledge B Vogelstein and K Polyak for providing WWP-luc and 0.7 kb PIG3 promoter constructs, as well as W Gallagher for critical reading of the manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Venot, C., Maratrat, M., Sierra, V. et al. Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. Oncogene 18, 2405–2410 (1999). https://doi.org/10.1038/sj.onc.1202539
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1202539
Keywords
This article is cited by
-
Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities
Nature Communications (2023)
-
Ell3 functions as a critical decision maker at the crossroad between stem cell senescence and apoptosis
Stem Cell Research & Therapy (2019)
-
Deconstructing networks of p53-mediated tumor suppression in vivo
Cell Death & Differentiation (2018)
-
Mechanisms of transcriptional regulation by p53
Cell Death & Differentiation (2018)
-
Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype
Nature Communications (2016)